Pli­ant’s chron­ic liv­er dis­ease drug has con­sis­tent safe­ty across dose ranges, PhII da­ta show

The high­est dose of Pli­ant Ther­a­peu­tics’ bex­ote­grast does not have im­proved ac­tiv­i­ty over low­er dos­es ac­cord­ing to new bio­mark­er da­ta from a mid-stage pri­ma­ry scle­ros­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER